Clarification request date:
June 01, 2026
Clarification:
- The clarification is provided pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Addresses news items dated May 29, 2026 and May 30, 2026 captioned "U.S. drug regulator flags data integrity, maintenance lapses at Dabur India plant"
- USFDA observations concern only a small part of the manufacturing plant at Silvassa, Dadra and Nagar Haveli
- The affected section generates insignificant revenue for the Company
- The plant continues to be operational despite the observations
- Company is actively engaged with USFDA on the audit findings
- A robust corrective and preventive action plan has been built and shared with USFDA
- Regular updates on progress are being shared with USFDA
- Strong controls are implemented to ensure quality systems are never compromised
- Company maintains highest standards of product quality across all manufacturing sites
- Commitment to optimal consumer experience reiterated
- No impact on financial, operational or other activities of the Company
- No other material event/information requiring disclosure under Regulation 30